BRAF and pilocytic astrocytoma: For example, the treatment of pilocytic astrocytomas dramatically changed when it was determined that the vast majority result from genetic alterations in the mitogen-activated protein kinase (MAPK) signaling pathway, most often in the BRAF gene, which serves as a therapeutic target [10,11,12,13,14,15].